ATE501252T1 - Verfahren zur inhibierung von tumorzellwachstum mit foxm1 sirns - Google Patents

Verfahren zur inhibierung von tumorzellwachstum mit foxm1 sirns

Info

Publication number
ATE501252T1
ATE501252T1 AT05705076T AT05705076T ATE501252T1 AT E501252 T1 ATE501252 T1 AT E501252T1 AT 05705076 T AT05705076 T AT 05705076T AT 05705076 T AT05705076 T AT 05705076T AT E501252 T1 ATE501252 T1 AT E501252T1
Authority
AT
Austria
Prior art keywords
foxm1b
tumor cell
sirna molecules
sirns
foxm1
Prior art date
Application number
AT05705076T
Other languages
English (en)
Inventor
Robert Costa
I-Ching Wang
Original Assignee
Univ Illinois
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Illinois filed Critical Univ Illinois
Application granted granted Critical
Publication of ATE501252T1 publication Critical patent/ATE501252T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT05705076T 2004-06-22 2005-01-06 Verfahren zur inhibierung von tumorzellwachstum mit foxm1 sirns ATE501252T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58214104P 2004-06-22 2004-06-22
PCT/US2005/000276 WO2006009575A1 (en) 2004-06-22 2005-01-06 METHODS OF INHIBITING TUMOR CELL PROLIFERATION WITH FOXM1 siRNA

Publications (1)

Publication Number Publication Date
ATE501252T1 true ATE501252T1 (de) 2011-03-15

Family

ID=34960668

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05705076T ATE501252T1 (de) 2004-06-22 2005-01-06 Verfahren zur inhibierung von tumorzellwachstum mit foxm1 sirns

Country Status (6)

Country Link
US (1) US20100098663A2 (de)
EP (2) EP1758999B1 (de)
JP (1) JP4852539B2 (de)
AT (1) ATE501252T1 (de)
DE (1) DE602005026811D1 (de)
WO (1) WO2006009575A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7635673B2 (en) 2003-03-25 2009-12-22 The Board Of Trustees Of The University Of Illinois Methods of inhibiting tumor cell proliferation
US8029980B2 (en) 2006-09-29 2011-10-04 The Board Of Trustees Of The University Of Illinois Identification and use of agents that modulate oncogenic transcription agent activity
WO2014157380A1 (ja) * 2013-03-27 2014-10-02 国立大学法人 長崎大学 創傷または線維症の治療剤
CN105392790B (zh) 2013-08-19 2019-04-19 豪夫迈·罗氏有限公司 4H-吡啶并[1,2-a]嘧啶-4-酮化合物制备用于预防或治疗癌症的药物的用途
EP3256126B1 (de) 2015-02-09 2024-03-27 F. Hoffmann-La Roche AG Verbindungen zur krebsbehandlung
EP3053577A1 (de) 2015-02-09 2016-08-10 F. Hoffmann-La Roche AG Verbindungen zur Krebsbehandlung
WO2024106737A1 (ko) * 2022-11-16 2024-05-23 한양대학교 에리카산학협력단 Foxm1 돌연변이체 또는 foxm1 shrna를 포함하는 암 치료용 약학 조성물

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
EP0088046B1 (de) 1982-02-17 1987-12-09 Ciba-Geigy Ag Lipide in wässriger Phase
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
EP0143949B1 (de) 1983-11-01 1988-10-12 TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION Pharmazeutische Zusammensetzung mit Gehalt an Urokinase
US4945050A (en) 1984-11-13 1990-07-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
CA1310924C (en) 1986-04-24 1992-12-01 Francis P. Mccormick Infective drug delivery system
US4970154A (en) 1987-10-09 1990-11-13 Baylor College Of Medicine Method for inserting foreign genes into cells using pulsed radiofrequency
US5672344A (en) 1987-12-30 1997-09-30 The Regents Of The University Of Michigan Viral-mediated gene transfer system
US5089475A (en) * 1989-02-07 1992-02-18 Brigham And Women's Hospital Treatment of ventilator dependency with growth hormone
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5676954A (en) 1989-11-03 1997-10-14 Vanderbilt University Method of in vivo delivery of functioning foreign genes
US5672510A (en) 1990-01-19 1997-09-30 Genetic Therapy, Inc. Retroviral vectors
US5151510A (en) 1990-04-20 1992-09-29 Applied Biosystems, Inc. Method of synethesizing sulfurized oligonucleotide analogs
US5849686A (en) * 1991-03-11 1998-12-15 Creative Biomolecules, Inc. Morphogen-induced liver regeneration
CA2135646A1 (en) 1992-05-11 1993-11-25 Kenneth G. Draper Method and reagent for inhibiting viral replication
EP1251170A3 (de) 1992-07-17 2002-10-30 Ribozyme Pharmaceuticals, Inc. Vergahren und Reagenz zur Behandlung von NF-kappaB abhängiger Tierischen Krankheiten
US5631236A (en) 1993-08-26 1997-05-20 Baylor College Of Medicine Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk
US5624803A (en) 1993-10-14 1997-04-29 The Regents Of The University Of California In vivo oligonucleotide generator, and methods of testing the binding affinity of triplex forming oligonucleotides derived therefrom
US5902880A (en) 1994-08-19 1999-05-11 Ribozyme Pharmaceuticals, Inc. RNA polymerase III-based expression of therapeutic RNAs
US5658785A (en) 1994-06-06 1997-08-19 Children's Hospital, Inc. Adeno-associated virus materials and methods
US6146886A (en) 1994-08-19 2000-11-14 Ribozyme Pharmaceuticals, Inc. RNA polymerase III-based expression of therapeutic RNAs
US5484720A (en) 1994-09-08 1996-01-16 Genentech, Inc. Methods for calcium phosphate transfection
CA2207593A1 (en) 1994-12-13 1996-06-20 John Gustofson Method and reagent for treatment of arthritic conditions, induction of graft tolerance and reversal of immune responses
EP0832269A1 (de) 1995-06-07 1998-04-01 Baylor College Of Medicine Nukleinsäure transporter zur abgabe von nukleinsäure in zellen
US6407062B1 (en) * 1995-09-27 2002-06-18 St. Jude Children's Research Hospital ARF-P19, a novel regulator of the mammalian cell cycle
US5723313A (en) * 1995-09-27 1998-03-03 St. Jude Children's Research Hospital ARF-p19, a novel regulator of the mammalian cell cycle
US5679559A (en) 1996-07-03 1997-10-21 University Of Utah Research Foundation Cationic polymer and lipoprotein-containing system for gene delivery
US5855920A (en) * 1996-12-13 1999-01-05 Chein; Edmund Y. M. Total hormone replacement therapy
US6395713B1 (en) 1997-07-23 2002-05-28 Ribozyme Pharmaceuticals, Inc. Compositions for the delivery of negatively charged molecules
CA2301166A1 (en) 1997-07-24 1999-02-04 Yuan-Peng Zhang Liposomal compositions for the delivery of nucleic acid catalysts
TW589189B (en) 1997-08-04 2004-06-01 Scras Kit containing at least one double-stranded RNA combined with at least one anti-viral agent for therapeutic use in the treatment of a viral disease, notably of viral hepatitis
EP1038016A2 (de) 1997-12-16 2000-09-27 Valentis Inc. Nadelloses injektion von formulierte nukleinsäure moleküle
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
US6613750B2 (en) * 1998-03-19 2003-09-02 Albert Einstein College Of Medicine Of Yeshiva University Method of inhibiting cell proliferation using an anti-oncogene protein
GB9827152D0 (en) 1998-07-03 1999-02-03 Devgen Nv Characterisation of gene function using double stranded rna inhibition
AU776150B2 (en) 1999-01-28 2004-08-26 Medical College Of Georgia Research Institute, Inc. Composition and method for (in vivo) and (in vitro) attenuation of gene expression using double stranded RNA
DE19956568A1 (de) 1999-01-30 2000-08-17 Roland Kreutzer Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
ATE408699T1 (de) 1999-03-10 2008-10-15 Phogen Ltd Verabreichung von nukleinsäuren und proteinen an zellen
WO2001029058A1 (en) 1999-10-15 2001-04-26 University Of Massachusetts Rna interference pathway genes as tools for targeted genetic interference
GB9927444D0 (en) 1999-11-19 2000-01-19 Cancer Res Campaign Tech Inhibiting gene expression
GB9930519D0 (en) * 1999-12-24 2000-02-16 Phogen Limited Uses of transport proteins
AU2002235175A1 (en) * 2000-12-06 2002-06-18 Tularik, Inc. Lometrexol combination therapy
US20040023390A1 (en) * 2002-08-05 2004-02-05 Davidson Beverly L. SiRNA-mediated gene silencing with viral vectors
AU2003258426B2 (en) * 2002-08-21 2008-04-10 The University Of British Columbia RNAi probes targeting cancer-related proteins
AU2003272247A1 (en) * 2002-08-28 2004-03-19 The Board Of Trustees Of The University Of Illinois Methods of treating age-related defects and diseases
EP2305813A3 (de) * 2002-11-14 2012-03-28 Dharmacon, Inc. Funktionale und hyperfunktionale siRNA
US7635673B2 (en) * 2003-03-25 2009-12-22 The Board Of Trustees Of The University Of Illinois Methods of inhibiting tumor cell proliferation
WO2005054870A2 (en) * 2003-11-26 2005-06-16 Vanderbilt University METHODS FOR ASSESSING p19-Arf INTERACTIONS WITH cMyc
WO2013180295A1 (ja) 2012-06-01 2013-12-05 日本電信電話株式会社 パケット転送処理方法およびパケット転送処理装置
US9507178B1 (en) 2013-08-29 2016-11-29 Charles Wesley Blackledge Electromagnetic waveguide assembly
US9300829B2 (en) 2014-04-04 2016-03-29 Canon Kabushiki Kaisha Image reading apparatus and correction method thereof

Also Published As

Publication number Publication date
WO2006009575A1 (en) 2006-01-26
US20100098663A2 (en) 2010-04-22
DE602005026811D1 (de) 2011-04-21
US20090075376A1 (en) 2009-03-19
JP2008503234A (ja) 2008-02-07
EP2298896A1 (de) 2011-03-23
EP1758999A1 (de) 2007-03-07
JP4852539B2 (ja) 2012-01-11
EP1758999B1 (de) 2011-03-09

Similar Documents

Publication Publication Date Title
ATE477337T1 (de) Zusammensetzungen und verfahren zur sirna-hemmung von icam-1
ATE501252T1 (de) Verfahren zur inhibierung von tumorzellwachstum mit foxm1 sirns
ATE507305T1 (de) Verfahren zur nukleinsäureimmobilisierung
ATE512146T1 (de) Phenylharnstoffderivate als hemmstoffe von tyrosinkinasen zur behandlung von tumorerkrankungen
ATE533502T1 (de) Verfahren zur modulation der il-23-aktivität; relevante reagenzien
WO2010031056A3 (en) Methods and compositions for modulating ire1, src, and abl activity
ATE469908T1 (de) Verfahren zur herstellung von pimecrolimus
ATE498685T1 (de) Antisense-oligonukleotide zur induktion von exon- skipping sowie verfahren zur verwendung davon
ATE397676T1 (de) Identifikation und verwendung von mirnas zur differenzierung myelogener leukämiezellen
DK2019692T3 (da) Forbindelser og fremgangsmåder til modulation af ekspression af gccr
ATE556711T1 (de) Verfahren zur verbesserung der hautqualität
EA200600591A1 (ru) МОДУЛИРОВАНИЕ ЭКСПРЕССИИ eIF4E
DE602005021336D1 (de) Verfahren zur identifizierung von proteinen mit stärkephosphorylierender enzymatischer aktivität
ATE406351T1 (de) Kondensierte heteroyralderivate zur verwendung als p38-kinase-inhibitoren
WO2005020921A3 (en) C-kit modulators and methods of use
DE602005020643D1 (de) Verfahren zur aktivierung von nkt-zellen
EA200701707A1 (ru) Пиразолопиримидины
TW200607513A (en) Certain chemical entities, compositions, and methods
BRPI0600777A (pt) método e sistema para a criação, armazenamento, gerenciamento e consumo de dados especìficos de cultura
DE602005019906D1 (de) Verfahren zur alkoxylierung von aktiven wasserstoff enthaltenden verbindungen und daraus hergestellte alkoxylierte verbindungen
ATE454458T1 (de) Pflanzen mit verbesserten wachstumseigenschaften und verfahren zu deren herstellung
ATE527378T1 (de) Antisense-modulation von p38-mitogen-aktivierter proteinkinase-expression
WO2006078422A3 (en) Methods for modulating tumor growth and metastasis
WO2005090572A3 (en) Compositions and methods for treating pancreatic cancer
DE60324207D1 (de) Verfahren zur identifizierung und/oder validierung von rezeptortyrosinkinase-inhibitoren

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties